Recent Memory and Aging Program News
See the latest news about Butler Hospital's Memory & Aging Program and how they are working towards a future without Alzheimer's disease through clinical research studies.
Providence Journal: Researcher Helps Pioneer Alzheimer's Diagnostic
With research bringing potential new treatments for Alzheimer’s disease, scientists including Butler Hospital’s Dr. Stephen P. Salloway have written criteria for the use of lumbar puncture in diagnosing the fatal disorder. Spinal taps, as they are commonly known, may be used in conjunction with PET scans and other diagnostic measures. Click here to learn more.
Imaging Agent Eli Lilly and Avid Radiopharmaceuticals, Inc. announced that a Phase 3 study of flortaucipir F 18, a Positron Emission Tomography (PET) imaging agent, met its two primary endpoints, defined as predicting brain tau pathology and predicting Alzheimer's disease diagnosis. The study, referred to as A16, enrolled a total of 156 end-of-life patients with dementia, mild cognitive impairment, or normal cognition who underwent flortaucipir PET imaging. The study met pre-specified endpoints with flortaucipir demonstrating statistically significant sensitivity and specificity for detecting tau pathology. Click here to learn more.
On Pluto: Inside the Mind of Alzheimer's
Join in a discussion and book signing with award-winning investigative reporter and author Greg O’Brien. Diagnosed with early-onset Alzheimer’s, O’Brien writes about living with the disease, not dying with it. And he does it with hope, faith, and humor. This is a complimentary event, but registration is required as seating is limited. Click here to register or call the Memory and Aging Program Outreach Team at (401) 455-6402. Click here to learn more.
Alzheimer’s is one of the deadliest, costliest, and most emotionally draining diseases in this country. Yet we have no drugs to reverse the condition, and the last medicine that came on the market to treat Alzheimer’s symptoms was approved some 15 years ago. Click here to learn more.
Associated Press - Hopes rise again for a drug to slow Alzheimer’s disease
Researchers from Biogen and Eisai announced Wednesday afternoon that the Phase 2 study of the investigational medication, BAN2401, showed promising results in removal of amyloid plaque and slowing the process of Alzheimer’s disease at the higher dosage. Click here to learn more.
U.S. study Aggressively lowering blood pressure significantly reduced the risk of mild cognitive impairment and dementia among hypertension patients in a large government-backed clinical trial, U.S. researchers said on Wednesday. Click here to learn more.
Eisai Co Ltd and Biogen Inc will move forward with late-stage clinical trials of their Alzheimer’s disease drug, BAN2401, and are working with regulators to design the next studies and gain expedited review as a breakthrough therapy. Click here to learn more.
New York Times - For Scientists Racing to Cure Alzheimer’s, the Math Is Getting Ugly
The task facing Eli Lilly, the giant pharmaceutical company, sounds simple enough: Find 375 people with early Alzheimer’s disease for a bold new clinical trial aiming to slow or stop memory loss. There are 5.4 million Alzheimer’s patients in the United States. You’d think it would be easy to find that many participants for a trial like this one.But it’s not. And the problem has enormous implications for treatment of a disease that terrifies older Americans and has strained families in numbers too great to count. Click here to learn more.
In response to the urgent need for more timely and accurate Alzheimer’s Disease diagnosis and improvement in patient care, the Alzheimer’s Association has developed 20 recommendations for physicians and NP’s. Click here to learn more.
No effective treatment for Alzheimer's is yet in sight, but better diagnostics, deeper scientific understanding and an encouraging drug trial are leading to a positive mood as the largest Alzheimer’s research conference of the year that began Sunday in Chicago. Click here to learn more.
AARP’s Brain Health Fund is investing $60 million in the Dementia Discovery Fund (DDF), which invests in research and development of breakthrough treatments for dementia. This move reflects AARP’s ongoing commitment to helping people with dementia and family caregivers, and makes AARP the single largest investor in the DDF. Click here to learn more.
Boston Globe Magazine: Can this doctor figure out how to stop Alzheimer’s before it starts?
Dr. Reisa Sperling, a lead researcher of Alzheimer’s disease and the head of the Center for Alzheimer’s Research and Treatment at Brigham and Women’s Hospital in Boston, talks about her personal and professional mission to find a cure for Alzheimer’s Disease. Click here to learn more.
WHAT IS MEMORY SUNDAY?
Memory Sunday, the SECOND SUNDAY IN JUNE, is a designated Sunday, within congregations serving African Americans, that provides education on Alzheimer’s: prevention, treatment, research studies and caregiving. To see the video of the June 10th Memory Sunday, that took place at the Berea SDA church in Dorchester, MA please click here: https://livestream.com/BereaBoston/events/8243683/videos/176123911
WJAR Ch. 10 - Health Check: New method of tackling Alzheimer's disease
There’s a possible new way to attack Alzheimer's disease. Dr. Stephen Salloway, Director of Butler Hospital's Memory and Aging Program discusses a trial that is looking at another important part of Alzheimer's disease - the tangles in the brain. Dr. Salloway notes that "over time the buildup of Tau protein causes nerve cells to get smaller and the brain to shrink, causing memory loss. The tangles are made up of Tau protein and that's what this treatment will attack.” Click here to learn more.
Providence Journal: ‘Swab party’ at Brown’s 50th reunion will aid research into Alzheimer’s disease
In what may be a national first, two members of the Brown University Class of 1968 will sponsor a “swab party” for 50th-reunion classmates who may wish to enroll in research studies aimed at preventing and curing Alzheimer’s disease. The event will include a presentation by Brown professor Dr. Stephen P. Salloway, head of Butler Hospital’s Memory and Aging Program, and the collection of a DNA sample from the cheeks of volunteers. Click here to learn more.
One of the single largest gifts in University history will drive research into brain and nerve disorders and establish one of the best-endowed brain institutes in the country. Brown University announced that alumnus and Trustee Robert J. Carney and his wife, Nancy D. Carney, have donated $100 million to our brain science institute. Click here to learn more.
Caregivers Journey Conference: Alzheimer's Association, Rhode Island Chapter
The 8th annual "Caregivers Journey" conference will take place on April 26th, 2018 at the Crowne Plaza in Warwick, RI. Dr. Stephen Salloway, Professor of Neurology and Psychiatry, Alpert Medical School of Brown University and Director of the Memory and Aging Program at Butler Hospital will deliver the conference's keynote address, "Developing Breakthroughs for Alzheimer's: What Rhode Islanders Can Do." The conference is free for caregivers. Click here to learn more.
77WABC Radio: Joan Hamburg: Joan Hamburg Interviews Dr. Salloway
Joan Hamburg interviews Dr. Stephen Salloway about new treatments and advancements that are being developed and it is something that can change this disease entirely. Click here to learn more.
RI State Plan Announcement: Lt. Governor McKee, Alzheimer's Association Secure $30K to Update State Plan on Alzheimer's
Lt. Governor McKee announced $30,000 in grants secured by his office and the Rhode Island chapter of the Alzheimer's Association to update the state's five-year plan on Alzheimer's Disease and Related Disorders. Tufts Health Plan Foundation and the Rhode Island Foundation each pledged $15,000 to support the initiative. Click here to learn more.
Facebook founder Mark Zuckerberg and his wife, Priscilla Chan, have launched a new effort with Stanford School of Medicine to fight Alzheimer’s disease and other neurodegenerative diseases. Click here to learn more.
The brightest minds in Alzheimer's research are meeting in Las Vegas for the Global Alzheimer's Platform Foundation's GAP-Net Site Optimization Conference from Feb 21 – 23. GAP-Net is a first-of-its-kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer's disease. GAP-Net currently has 63 leading academic and private research site partners throughout North America. Click here to learn more.
University of Rhode Island: Executive Director of URI’s Ryan Institute receives prestigious honor from national science peers - Paula Grammas, executive director of the University of Rhode Island’s George & Anne Ryan Institute for Neuroscience, has been elected a Fellow of the American Association for the Advancement of Science in recognition of her pioneering research into neurodegenerative conditions, including Alzheimer’s disease. Click here to learn more.
National Institute on Aging (NIA): New National Institutes of Health consortium award to enhance clinical trials for Alzheimer’s disease, related dementias. - The National Institutes of Health (NIH) has announced a new clinical trials consortium expected to accelerate and expand studies of therapies in Alzheimer’s and related dementias. The Alzheimer’s Clinical Trial Consortium (ACTC) will be lead jointly by research teams from the University of Southern California Alzheimer’s Therapeutic Research Institute (ATRI), San Diego, Harvard- affiliated Brigham and Women’s Hospital and Massachusetts General Hospital, Boston and Mayo Clinic, Rochester, Minnesota.
The ACTC experts and infrastructure will support the design and conduct of trials across the full spectrum of Alzheimer’s and related dementias, from prevention initiatives to combination trials for advanced symptomatic stages. The ACTC will also include a Minority Outreach and Recruitment Team that will enhance and support both central and local partnerships with diverse communities, to include and benefit everyone affected by Alzheimer’s disease. The consortium currently includes 35 sites in 24 states and the District of Columbia. Click here to learn more.
Providence Journal - RI Seeks New Way to Diagnosis, Prevent Alzheimer’s Disease - Butler’s Memory and Aging Program enrolled its first participant in a retinal imaging trial that’s studying whether an investigational medication can lower amyloid plaques in the brain as well as in the retina for those at risk of developing the disease. If successful, retinal imaging may have the ability to be a more cost-effective way to detect and monitor AD risk and prevention.
ABC 6 News (WLNE-TV, Providence) - Brown University Alzheimer's Study May Lead to Early Detection
Facing Dementia is a five part television series airing on Channel NewsAsia, an English Language TV news channel based in Singapore. The series follows several families as they navigate through diagnosis, caregiving and treatment of loved ones affected by different types of dementia. In this episode, What the Future Holds, Dr. Stephen Salloway discusses the current and future state of Alzheimer’s research as scientists worldwide work together to find a cure. We’re also introduced to two families from the Memory and Aging Program that are participating in different clinical trials, but that have similar goals of slowing down or preventing Alzheimer’s disease.
Also reported by:
The Providence Journal EDITORIAL – “Editorial: R.I. battles Alzheimer's”
NBC Channel 10 – “Health Check: Alzheimer's disease treatment”
Science News – “New Alzheimer’s drug shows promise in small trial”
Huffington Post – “New Drug Clears Abnormal Brain Proteins Tied To Alzheimer’s”
Brown University – “Rhode Island’s role in promising new Alzheimer’s results”
Scientific American – “Alzheimer's Drug Shows Promise in Small Trial”“Fármaco para el Alzhéimer va a estar disponible a la venta en unos años: Stephen Salloway”